Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)
A Randomized, Worldwide, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Immunogenicity, and Efficacy on the Incidence of HPV 16/18-Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 23-Year Old Women - The FUTURE II Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease)
Sponsor: Merck Sharp & Dohme LLC
Listed as NCT00092534, this PHASE3 trial focuses on Cervical Cancer and Genital Warts and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 13 times since 2002, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Mar 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Mar 2025 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Sep 2022 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 8 earlier versions
-
Jun 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE3
-
Apr 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
Status: Completed → Active Not Recruiting
-
Jan 2020 — Apr 2020 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2020 [monthly]
Completed PHASE3
-
Jul 2017 — Jun 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Jun 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.